Healthcare / Drug Manufacturers - Specialty & Generic
Exclusive insider sentiment analysis for the Drug Manufacturers - Specialty & Generic sector. Track real-time Director purchases and institutional money flow to identify high-conviction opportunities before the market reacts.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-24 20:30 | 2026-07-23 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $528.58 | 9,500 | $5,021,520 | 324,443 | -2.8% |
| 2026-07-23 20:36 | 2026-07-22 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $530.57 | 9,500 | $5,040,380 | 324,443 | -2.8% |
| 2026-07-22 20:30 | 2026-07-21 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $532.24 | 9,500 | $5,056,298 | 324,443 | -2.8% |
| 2026-07-21 20:35 | 2026-07-20 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $531.69 | 9,500 | $5,051,035 | 324,443 | -2.8% |
| 2026-07-20 20:30 | 2026-07-17 | HIMS | Hims & Hers Health, Inc. | Okupe Oluyemi | Officer; Chief Financial Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $31.99 | 7,163 | $229,168 | 284,321 | -2.5% |
| 2026-07-20 20:32 | 2026-07-17 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $537.05 | 9,500 | $5,101,940 | 324,443 | -2.8% |
| 2026-07-17 23:29 | 2026-07-15 | INM | InMed Pharmaceuticals Inc. | ADAR1 Capital Management, LLC | 10% owner | Drug Manufacturers - Specialty & Generic | BUY | $1.56 | 1,000 | $1,555 | 801,000 | +0.1% |
| 2026-07-17 20:30 | 2026-07-16 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $530.91 | 9,500 | $5,043,689 | 324,443 | -2.8% |
| 2026-07-17 17:15 | 2026-07-15 | AQST | Aquestive Therapeutics, Inc. | Barber Daniel | Officer; President and CEO | Drug Manufacturers - Specialty & Generic | SALE | $4.01 | 25,000 | $100,193 | 610,574 | -3.9% |
| 2026-07-17 01:58 | 2026-07-14 | INM | InMed Pharmaceuticals Inc. | Vivo Opportunity, LLC | 10% owner | Drug Manufacturers - Specialty & Generic | BUY | $1.55 | 20,546 | $31,846 | 75,019 | +37.7% |
| 2026-07-16 21:14 | 2026-07-14 | ETON | Eton Pharmaceuticals, Inc. | Opaleye Management Inc. | 10% owner | Drug Manufacturers - Specialty & Generic | SALE | $37.54 | 28,315 | $1,063,033 | 40,000 | -41.4% |
| 2026-07-16 20:30 | 2026-07-16 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer; EVP & GENERAL COUNSEL | Drug Manufacturers - Specialty & Generic | OPT+S | $533.69 | 8,300 | $4,429,638 | 45,172 | -15.5% |
| 2026-07-16 20:30 | 2026-07-15 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $530.35 | 9,500 | $5,038,340 | 324,443 | -2.8% |
| 2026-07-15 21:00 | 2026-07-14 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $526.83 | 9,500 | $5,004,909 | 40,513 | -19.0% |
| 2026-07-15 19:36 | 2026-07-13 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP | 10% owner | Drug Manufacturers - Specialty & Generic | SALE | $4.48 | 83,149 | $372,707 | 0 | -100.0% |
| 2026-07-14 20:34 | 2026-07-13 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $535.99 | 9,500 | $5,091,950 | 40,513 | -19.0% |
| 2026-07-14 20:02 | 2026-07-13 | ANIP | ANI PHARMACEUTICALS INC | Cook Meredith | Officer; SR. VP, GENERAL COUNSEL & SEC. | Drug Manufacturers - Specialty & Generic | SALE | $81.84 | 500 | $40,920 | 77,390 | -0.6% |
| 2026-07-13 20:31 | 2026-07-10 | INDV | Indivior Pharmaceuticals, Inc. | Heidbreder Christian | Officer; Chief Scientific Officer | Drug Manufacturers - Specialty & Generic | SALE | $41.14 | 18,586 | $764,628 | 209,337 | -8.2% |
| 2026-07-13 20:33 | 2026-07-10 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $544.60 | 9,500 | $5,173,660 | 40,513 | -19.0% |
| 2026-07-13 20:27 | 2026-07-09 | NBIX | NEUROCRINE BIOSCIENCES INC | Lippoldt Darin | Officer; Chief Legal Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $179.60 | 10,000 | $1,796,014 | 54,729 | -15.4% |
| 2026-07-13 20:27 | 2026-07-10 | NBIX | NEUROCRINE BIOSCIENCES INC | Delaet Ingrid | Officer; Chief Regulatory Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $181.02 | 4,367 | $790,514 | 16,225 | -21.2% |
| 2026-07-13 20:00 | 2026-07-09 | AMLX | Amylyx Pharmaceuticals, Inc. | Mazzariello Gina | Officer; Chief Legal Officer | Drug Manufacturers - Specialty & Generic | SALE | $17.96 | 30,000 | $538,866 | 179,090 | -14.3% |
| 2026-07-13 20:03 | 2026-07-10 | RDHL | RedHill Biopharma Ltd. | Raday Gilead | Officer; Chief Operating Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $0.00 | 14,130,000 | $1,413 | 218,780,000 | -6.1% |
| 2026-07-13 18:34 | 2026-07-09 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP | 10% owner | Drug Manufacturers - Specialty & Generic | BUY | $3.36 | 8,997 | $30,213 | 61,271 | +17.2% |
| 2026-07-10 20:02 | 2026-07-10 | UTHR | UNITED THERAPEUTICS Corp | MALCOLM JAN | Director | Drug Manufacturers - Specialty & Generic | OPT+S | $550.59 | 325 | $178,942 | 450 | -41.9% |
| 2026-07-10 01:26 | 2026-07-09 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $551.13 | 9,500 | $5,235,756 | 40,513 | -19.0% |
| 2026-07-09 22:41 | 2026-07-07 | NBIX | NEUROCRINE BIOSCIENCES INC | Delaet Ingrid | Officer; Chief Regulatory Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $178.65 | 14,571 | $2,603,112 | 16,225 | -47.3% |
| 2026-07-09 21:50 | 2026-07-07 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP | 10% owner | Drug Manufacturers - Specialty & Generic | SALE | $3.45 | 29,111 | $100,459 | 52,274 | -35.8% |
| 2026-07-09 20:30 | 2026-07-08 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $553.17 | 9,500 | $5,255,111 | 40,513 | -19.0% |
| 2026-07-09 20:32 | 2026-07-07 | IRWD | IRONWOOD PHARMACEUTICALS INC | Silver Ronald | Officer; PFO & PAO | Drug Manufacturers - Specialty & Generic | SALE | $4.52 | 127,890 | $578,063 | 313,680 | -29.0% |
| 2026-07-08 20:47 | 2026-07-07 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $558.87 | 9,500 | $5,309,295 | 40,513 | -19.0% |
| 2026-07-07 22:29 | 2026-07-02 | ETON | Eton Pharmaceuticals, Inc. | Opaleye Management Inc. | 10% owner | Drug Manufacturers - Specialty & Generic | SALE | $37.64 | 126,685 | $4,768,639 | 53,315 | -70.4% |
| 2026-07-07 20:20 | 2026-07-06 | HIMS | Hims & Hers Health, Inc. | Okupe Oluyemi | Officer; Chief Financial Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $36.49 | 7,163 | $261,351 | 284,321 | -2.5% |
| 2026-07-07 20:23 | 2026-07-06 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP | 10% owner | Drug Manufacturers - Specialty & Generic | SALE | $3.51 | 9,022 | $31,667 | 81,385 | -10.0% |
| 2026-07-07 20:23 | 2026-07-02 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP | 10% owner | Drug Manufacturers - Specialty & Generic | BUY | $3.54 | 7,851 | $27,793 | 90,407 | +9.5% |
| 2026-07-07 13:10 | 2026-07-06 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $548.96 | 9,500 | $5,215,133 | 40,513 | -19.0% |
| 2026-07-07 01:40 | 2026-07-02 | ANIP | ANI PHARMACEUTICALS INC | CAREY STEPHEN P. | Officer; SVP & CFO | Drug Manufacturers - Specialty & Generic | OPT+S | $86.00 | 3,313 | $284,918 | 177,543 | -1.8% |
| 2026-07-06 20:48 | 2026-07-06 | ALKS | Alkermes plc. | Gaffin David Joseph | Officer; EVP, CLO, Alkermes, Inc. | Drug Manufacturers - Specialty & Generic | SALE | $54.03 | 2,034 | $109,897 | 227,490 | -0.9% |
| 2026-07-02 20:32 | 2026-07-02 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer; EVP & GENERAL COUNSEL | Drug Manufacturers - Specialty & Generic | OPT+S | $552.56 | 8,300 | $4,586,275 | 45,172 | -15.5% |
| 2026-07-02 20:31 | 2026-07-01 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $543.66 | 9,500 | $5,164,789 | 40,513 | -19.0% |
| 2026-07-02 23:02 | 2026-06-30 | INM | InMed Pharmaceuticals Inc. | Vivo Opportunity, LLC | 10% owner | Drug Manufacturers - Specialty & Generic | BUY | $1.55 | 6,551 | $10,148 | 73,135 | +9.8% |
| 2026-07-02 21:47 | 2026-07-02 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $554.61 | 9,500 | $5,268,781 | 40,513 | -19.0% |
| 2026-07-02 17:37 | 2026-07-01 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP | 10% owner | Drug Manufacturers - Specialty & Generic | BUY | $3.30 | 3,959 | $13,065 | 82,556 | +5.0% |
| 2026-07-02 16:57 | 2026-07-01 | EBS | Emergent BioSolutions Inc. | Williams Paul Anthony | Officer; SVP, Products Business | Drug Manufacturers - Specialty & Generic | SALE | $8.40 | 3,000 | $25,200 | 159,098 | -1.9% |
| 2026-07-01 20:27 | 2026-06-29 | BIOA | BioAge Labs, Inc. | Barton Shane | Officer; Principal Accounting Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $25.20 | 62,566 | $1,576,751 | 0 | -100.0% |
| 2026-07-01 23:17 | 2026-06-29 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP | 10% owner | Drug Manufacturers - Specialty & Generic | BUY | $3.40 | 32,591 | $110,695 | 78,597 | +70.8% |
| 2026-07-01 22:29 | 2026-07-01 | ALKS | Alkermes plc. | Hopkinson Craig C. | Officer; EVP R&D, Chief Medical Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $51.51 | 9,000 | $463,621 | 73,389 | -10.9% |
| 2026-07-01 20:31 | 2026-06-30 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $541.00 | 9,500 | $5,139,542 | 40,513 | -19.0% |
| 2026-07-01 20:34 | 2026-06-29 | AKBA | Akebia Therapeutics, Inc. | Ostrowski Erik | Officer; SVP, CFO, CBO & Treasurer | Drug Manufacturers - Specialty & Generic | SALE | $1.11 | 56,019 | $62,181 | 616,616 | -8.3% |
| 2026-06-30 20:52 | 2026-06-26 | NBIX | NEUROCRINE BIOSCIENCES INC | Lippoldt Darin | Officer; Chief Legal Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $170.15 | 10,000 | $1,701,492 | 54,729 | -15.4% |
Strategic Analysis
Analyzing insider transactions within the Drug Manufacturers - Specialty & Generic sector provides critical insights into institutional sentiment. When multiple executives across different companies in the same industry exhibit similar buying patterns (cluster buying), it often signals an upcoming sector-wide recovery or undervalued market conditions.
Regulatory Transparency
Our platform tracks SEC Form 4 filings in real-time. We differentiate between routine option exercises and open-market purchases to give you a clear view of "Skin in the Game". Understanding the roles of Directors vs. 10% Owners helps prioritize signals that carry the most predictive weight.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.